SU2C Genomics-Enabled Medicine for Melanoma (GEMM) Trial. SU2C Genomics-Enabled Medicine for Melanoma (GEMM) Trial

The goal of the GEMM Trial is to ascertain if comprehensive and systematic interrogation of a patient's tumor molecular profile improves outcomes compared to the current practice of physician's choice for metastatic melanoma patients who have progressed following first line therapy. The data shared here includes tumor/normal exome and tumor RNAseq data for the trial patients, as well as archival data for a subset of patients.